Use of GnRH antagonist (cetrorelix®) in controlled ovarian hyperstimulation in women with polycystic ovary disease;Utilisation des antagonistes de la GnRH (cetrorelix®) dans la stimulation plurifolliculaire chez les patientes porteuses d'une dystrophie ovarienne micropolykystique

Tunisie Medicale

Volumn 86, Issue 12, 2008, Pages 1060-1065

  Kdous, Moez ^a   M'solly, Sana ^a   Zhioua, Fethi ^a   Meriah, Sadok ^a  

^a Hopital Aziza Othmana   (Tunisia)

Author keywords

Cetrorelix; GnRH antagonists; ICSI; PCOS

Indexed keywords

CETRORELIX; CHORIONIC GONADOTROPIN; ESTROGEN; GONADORELIN DERIVATIVE; RECOMBINANT FOLLITROPIN; TRIPTORELIN; DRUG DERIVATIVE; GONADORELIN; HORMONE ANTAGONIST;

AGED; ARTICLE; CONTROLLED STUDY; EVALUATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OOCYTE; OVARY FOLLICLE; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; PREGNANCY RATE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; ADULT; METHODOLOGY; OVULATION INDUCTION; PREGNANCY;

ADULT; FEMALE; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY RATE; RETROSPECTIVE STUDIES;

EID: 63249084630     PISSN: 00414131     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Bouchard P, Charbonnel B, Caraty A, et al. The role of LHRH during the preovulatory period : a basis for the use of LHRH antagonists in ovulation induction. Fertil Steril 1994; 5: 87-93.
2. FIVNAT. Comparaison agonistes antagonistes dans les stimulations pour FIV. Gynécol Obstét Fertil 2004 ; 32 : 737-40.
3. The European and meaddle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 2001; 16: 644-51.
4. . The European Orgalutran Study Group. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient results of a controlled, randomized, multicentre trial. Hum Reprod 2000; 15: 1490-8.
5. Ragni G, Vegetti W, Riccaboni A, Engl B, Brigante C, Crosignani PG. Comparaison of GnRH agonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome. Human Reproduction 2005; 20: 2421-5. (Pubitemid 41222487)
6. Bahceci M, Ulug U, Ben-Shlomo I, Erden HF, Akman M. Use of GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study. Journal of reproductive medicine 2005; 50: 84-90.
7. Al-Inany HG, Abou-setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. Hum Reprod 2006; 18: 487-97.
8. The North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 2001; 75: 38-45.
9. Olivennes F, Fanchin R, Bouchard P, Taieb J, Frydman R. Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist. Fertil Steril 1996; 66: 151-3.
10. Albano C, Felberbaum RE, Smitz J, et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod 2000; 15: 526-31.
11. Devaux A, Pouly JL, Bachelot A, Mourouvin Z, De Mouzon J. Les antagonistes du GnRH: effets biologiques. Gynécol Obstét Fertil 2004 ; 32 : 741-47. (Pubitemid 39248626)
12. Rajkumar K, Dheen T, Kresk M, Murphu LJ. Impaired estrogen action in the uterus og IGF binding protein-1 transgenic mice. Endocrinology 1996; 137: 1258-64.
13. Ohlsson R, Holmgren L, Glaser A, Szpecht A, Pfeifer-Ohlsson S. IGFII and short- range stimulatory loops in control of human placental growth. EMBO J 1989; 8: 1993-9.